{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.391","upperLimit":"0.608","value":"0.50"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0.042","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"description":"Response is defined as complete response (CR), very good partial response (VGPR) or partial response (PR).\n\nCR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and \\<=5% plasma cells in bone marrow VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-component plus urine M-component \\< 100 mg per 24 hours\n\nPR:\n\n* ≥ 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \\< 200 mg per 24 hours\n* If followed by free light chain (FLC) only, a ≥ 50% decrease in the difference between involved and uninvolved FLC levels\n* If unmeasurable disease by serum M-protein, urine M-protein, and serum FLC at baseline, a ≥50% reduction in plasma cells provided baseline bone marrow percentage was ≥ 30%\n* If present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A (Lenalidomide; Phase III)"},{"description":"Patients undergo observation until progression to symptomatic myeloma.","id":"OG001","title":"Arm B (Observation; Phase III)"}],"paramType":"NUMBER","populationDescription":"Among randomized patients who received treatment or observation","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then annually for years 6-10","title":"Proportion of Participants With Response (Phase III Secondary Endpoint)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}